Alnylam Pharmaceuticals
Latest round
- Series B
Last raised
- Jul 2002
Total raised
- $15M
Investors
- 4
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc.Founded in 2002 and headquartered in Cambridge, US, Alnylam Pharmaceuticals specializes in RNAi therapeutics.00 mn across six investment deals, with the most recent deal occurring on May 28, 2004.Alnylam Pharmaceuticals specializes in developing and commercializing innovative RNA interference (RNAi) therapeutics, focusing on conditions caused by gene dysfunction. Its key products include AMVUTTRA® (vutrisiran) for hereditary transthyretin-mediated amyloidosis (hATTR) and Qfitlia™ (fitusiran) for hemophilia.29 mn.14 mn for the same year.Alnylam Pharmaceuticals is focused on expanding its product portfolio and market reach. The company plans to launch additional RNAi therapeutics targeting various genetic disorders in the near future.00 mn, Alnylam aims to enhance its research and development efforts, expand into new geographic markets, and further its mission of addressing unmet medical needs. The firm is particularly interested in entering markets in Europe and Asia by 2025, leveraging strategic partnerships to facilitate access to its innovative treatments.
Who invested in Alnylam Pharmaceuticals
4 investors across 2 rounds
See all investors in Alnylam Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alnylam Pharmaceuticals
Who invested in Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alnylam Pharmaceuticals last raise money?
Alnylam Pharmaceuticals's most recent round on record is a Series B, in Jul 2002.
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals is a biotechnology company.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in Cambridge, US.
Which VCs invest in companies like Alnylam Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Alnylam Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Alnylam Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.